Opinion

Video

Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies

An examination of results from key studies in the DLBCL landscape are conducted by Dr Fred Locke.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    • Please discuss the data supporting CAR T-cell therapy as the primary 2Ltreatment option for patients who are transplant-eligible and have primary refractory or early relapse R/R DLBCL.
      • Please review the latest 56-month follow-up data of the ZUMA-7study, evaluating axi-cel.
        • ASH 2024 Update: Subgroup Analysis of the ZUMA-7 study.
        • Please discuss the subsequent cellular immunotherapy off-protocol in the SOC arm.
    • Please review the 36-month follow-up data of the TRANSFORM study, evaluating liso-cel.
      • ASCO 2024 Update: Subgroup analysis of the TRANSFORM study [primary refractory vs. early relapsed].
    • What were some key takeaways from the results of these two studies?

    Newsletter

    Stay up to date on the most recent and practice-changing oncology data

    Related Content